| P50 | author | Leonardo Roever | Q52097086 |
| P2093 | author name string | Marconi Abreu | |
| | Andre Rodrigues Duraes | |
| | Joaquim Silva Custodio | |
| | Natalia Albuquerque Rocha | |
| P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| | Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 |
| | Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 |
| | Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association | Q30238784 |
| | Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association | Q30249059 |
| | Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans | Q33356608 |
| | The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota | Q33825297 |
| | Heart failure in the diabetic population - pathophysiology, diagnosis and management | Q33935375 |
| | SGLT2 mediates glucose reabsorption in the early proximal tubule. | Q34457264 |
| | Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 |
| | Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 |
| | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 |
| | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 |
| | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 |
| | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 |
| | Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus | Q36622125 |
| | Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. | Q36654675 |
| | Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs | Q36783681 |
| | Epidemiology and aetiology of heart failure | Q36905978 |
| | Metabolic dysfunction in diabetic cardiomyopathy | Q36930481 |
| | Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options | Q37055775 |
| | Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial | Q37106527 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial | Q37302078 |
| | Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes | Q37532095 |
| | The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. | Q38262227 |
| | Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot | Q38376619 |
| | Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes | Q38723450 |
| | Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 |
| | IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. | Q38822669 |
| | Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. | Q38912082 |
| | Renal, metabolic and cardiovascular considerations of SGLT2 inhibition | Q39035951 |
| | Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms | Q39318765 |
| | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 |
| | Diabetes and cardiovascular disease. The Framingham study | Q41509493 |
| | Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 |
| | Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial | Q43804231 |
| | Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged | Q44009242 |
| | The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality | Q44520653 |
| | Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure | Q46707691 |
| | Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 |
| | Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? | Q47384272 |
| | Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes | Q48126574 |
| | How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial | Q48184186 |
| | Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. | Q50955035 |
| | EMPA-REG OUTCOME: The Cardiologist's Point of View. | Q50991867 |
| | Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 |
| | Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. | Q51355578 |
| | Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. | Q51382208 |
| | CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Q51707689 |
| | Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. | Q51832630 |
| | Diabetes Mellitus and Heart Failure. | Q52867555 |
| | Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors | Q63071417 |
| P433 | issue | 3 | |
| P304 | page(s) | 409-418 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Heart Failure Reviews | Q2167497 |
| P1476 | title | SGLT2 inhibition and heart failure-current concepts | |
| P478 | volume | 23 | |